Found: 5
Select item for more details and to access through your institution.
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 6, p. 1253, doi. 10.1007/s40121-024-00970-x
- By:
- Publication type:
- Article
Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011–2018.
- Published in:
- PLoS ONE, 2021, v. 16, n. 4, p. 1, doi. 10.1371/journal.pone.0250010
- By:
- Publication type:
- Article
Prevalence of Pneumococcal Serotypes in Community-Acquired Pneumonia among Older Adults in Italy: A Multicenter Cohort Study.
- Published in:
- Microorganisms, 2023, v. 11, n. 1, p. 70, doi. 10.3390/microorganisms11010070
- By:
- Publication type:
- Article
Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 7, p. 1247, doi. 10.1093/cid/ciac899
- By:
- Publication type:
- Article